Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Pulmonary Aspergillosis with Nonneutropenic Patients

Table 1

Baseline clinical characteristics of the study population.

	IPA; (), (%)	Non-IPA; (), (%)
Age, mean years	58.97	55.62
Male gender	20 (64.5)	82 (53.9)
High-risk environment exposed	2 (6.5)	1 (0.7)
Underlying disease
Emphysema	5 (16.1)	22 (14.5)
COPD	1 (3.2)	8 (5.3)
Bronchial asthma	0	8 (5.3)
Pulmonary tuberculosis	2 (6.5)	10 (6.6)
Solid tumor	3 (9.7)	8 (5.3)
Bronchiectasis	3 (9.7)	24 (15.8)
Diabetes	5 (16.1)	16 (10.5)
Liver cirrhosis	0	1 (0.7)
Hematologic malignancy	0	1 (0.7)
Autoimmune disease	2 (6.5)	2 (1.3)
Kidney non-malignant disease	0	3 (2.0)
Organ failure	2 (6.5)	1 (0.7)
No underlying disease	9 (29.0)	57 (37.5)
Final diagnosis
	Proven: 0	ABPA: 1 (0.7)
	Probable: 10 (32.3)	Aspergilloma: 3 (2.0)
	Possible: 21 (67.7)	Colonization or contamination: 5 (3.3)
		Others: 143 (94.1)

IPA, invasive pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; ABPA, allergic bronchopulmonary aspergillosis. Date are number (%) of patients, unless otherwise indicated.